Introduction
============

Since the early 2000s, the introduction of newly developed agents has dramatically improved the outcome of patients with multiple myeloma. However, the refractory/relapsed multiple myeloma (RRMM) remains a big challenge, due to its biological and clinical complexity. In an attempt to find ways to conquer RRMM, world's leading hematologists have performed many randomized controlled trials (RCTs) worldwide. Recently, two research groups have tried to synthesize the results of these trials by network meta-analysis (NMA), a statistical analysis method by which a thorough comparison and ranking of all included treatment options is made possible.[@b1-cmar-10-2817],[@b2-cmar-10-2817] However, the two previous NMAs have certain limitations. To name a few, in the NMA by van Beurden-Tan et al,[@b1-cmar-10-2817] important outcomes such as overall survival (OS) were left uninvestigated and the ranking information was not provided; and in the other NMA by Botta et al,[@b2-cmar-10-2817] regimens were grouped into categories before comparison, some of which seem inappropriate and may cause bias and confusion. Besides, we found that several new RCTs and updated trial reports are available for a new NMA. Considering the above, we performed the present study to update the evidence and improve its quality using traditional NMA and a self-designed weighted average method to rank the regimens by summarizing results across various efficacy outcome measures.

Materials and methods
=====================

Outcome measures
----------------

This updated NMA focuses on early and long-term efficacy outcomes, including the nonresponse rate (NRR), time to progression (TTP), progression-free survival (PFS) and OS. Response rate was considered instead of NRR because its outcome event, that is, the absence of objective response to treatment, a negative indicator of treatment efficacy and prognosis, is similar to events of other outcome measures, which allows ranking by summarizing results across all these outcome measures.

Literature search and study selection
-------------------------------------

The PubMed database was searched. We adopted the literature search strategy described by Botta et al.[@b2-cmar-10-2817] In brief, all possible combinations of the following search terms were used for searching RCTs concerning RRMM patients: "multiple myeloma," "relapse," "refractory," "randomized," "management," "regimen," and "therapy." No specific filters were used during the search. The time range of the search was between the January 1, 2000 and June 30, 2017.

The following predefined eligibility criteria were used for the study selection: 1) the study should be an RCT; 2) the subjects should be RRMM patients; 3) at least two different regimens were compared in the study, except for those comparing different dosing schemes or modes of administrations; 4) data for at least one of the outcome measures were available. Studies that did not match any of the above criteria were excluded.

Two authors (X.W.L. and X.Q.D.) independently performed the literature search and study selection and discussed with the third author (X.M.) to resolve any discrepancies.

Data extraction and statistical analysis
----------------------------------------

Two authors (X.W.L. and X.Q.D) independently reviewed the reports. Supplementary materials of the RCTs were included, and the following information was extracted from each study report: name of the first author, year of publication, trial identifications, treatment regimens used for the experimental and control arms, total number of patients, outcome measures investigated, and data for the calculation of effect size for each outcome.

Before NMA, the logarithmic odds ratio (OR) and its standard error were calculated for NRR, and the logarithmic hazard ratio (HR) and its standard error for time-to-event outcomes were original data inputs. Fixed effects Bayesian NMAs were conducted, and forest plots were generated with results shown as the HR and corresponding 95% credible interval (95%CrI). To include all treatments within one network, bortezomib with or without dexamethasone was considered identical and labeled as "bortezomib ± dexamethasone" and thalidomide with or without dexamethasone was considered identical and labeled as "thalidomide ± dexamethasone" as described in van Beurden-Tan et al.[@b1-cmar-10-2817] The dexamethasone monotherapy was set as the common reference regimen. To rank all regimens, the surface under the cumulative ranking curve (SUCRA) was calculated for each outcome as described in Salanti et al [@b3-cmar-10-2817] for a given regimen. A larger SUCRA score indicated better efficacy in terms of a specific outcome measure. For the final ranking regarding the overall efficacy, an arithmetic weighted average of SUCRA scores across NRR, PFS, and OS was calculated. A 20%, 35%, and 45% weight was given to the NRR, PFS, and OS, respectively. These weights were given in accordance with the importance of the outcome measures. We considered the OS the most important, PFS as the surrogate of OS the second most important, and NRR that reflects the early efficacy the least important. There was only one exception, oblimersen plus dexamethasone, for which data on PFS and OS were not available, thus an 80% weight was attributed to TTP. A larger weighted average of SUCRAs indicated a higher rank in terms of overall efficacy. The R software version 3.1.2 and the gemtc package were used to perform all the statistical analyses.

Results
=======

Basic information of included RCTs
----------------------------------

After literature search and study selection, a total of 29 trial reports published between 2005 and 2017 were considered eligible to be included in the NMA. As a result, 24 independent studies, with a total of 10,853 subjects and 21 different regimens were included in the present study. Compared with the inclusion results by Botta et al,[@b2-cmar-10-2817] an additional seven references[@b4-cmar-10-2817]--[@b10-cmar-10-2817] were included, among which four were newly identified studies[@b4-cmar-10-2817],[@b5-cmar-10-2817],[@b9-cmar-10-2817],[@b10-cmar-10-2817] and three were updated study results.[@b6-cmar-10-2817]--[@b8-cmar-10-2817] The basic information of the included references has been summarized in [Table 1](#t1-cmar-10-2817){ref-type="table"}.

NMA results
-----------

According to the results of NMAs, the combination of daratumumab, lenalidomide, and dexamethasone was the most effective therapy in terms of NRR, TTP, and PFS (NRR: OR =0.046, 95% CrI =\[0.024, 0.085\]; TTP: HR =0.14, 95% CrI =\[0.092, 0.2\]; PFS: HR =0.12, 95% CrI =\[0.077, 0.18\], compared with dexamethasone singlet; [Figure 1A--C](#f1-cmar-10-2817){ref-type="fig"}), and the combination of ixazomib, lenalidomide, and dexamethasone is the most effective one in terms of OS (HR =0.12, 95%CrI =\[0.17, 0.54\]; [Figure 1D](#f1-cmar-10-2817){ref-type="fig"}).

Ranking of regimens by SUCRA
----------------------------

As shown in [Table 2](#t2-cmar-10-2817){ref-type="table"}, the ranking by SUCRA scores for each efficacy outcome was generally consistent with NMA findings. The combination of daratumumab, lenalidomide, and dexamethasone ranked first for NRR (SUCRA =0.984), TTP (SUCRA =0.988), and PFS (SUCRA =0.999). The combination of ixazomib, lenalidomide, and dexamethasone ranked first for OS (SUCRA =0.972).

In terms of overall efficacy measured by the weighted average of SUCRAs, the combination of daratumumab, lenalidomide, and dexamethasone ranked on top (weighted average =0.920), followed by the combination of ixazomib, lenalidomide, and dexamethasone (weighted average =0.907).

Discussion
==========

Regardless of recent progress in management, RRMM is still an incurable disease, which has been attracting substantial research attention. In the past decades, a large number of RCTs concerning RRMM treatment were published, in which dozens of novel therapeutic regimens were tested and examined. Efforts were made to quantitatively summarize the evidence from RCTs by performing NMA, in order to provide useful and important information for clinical decision-making at minimal cost. However, flawed analyses may result in misleading conclusions. On the other hand, updates of NMAs on a timely basis are the key to keep the evidence "alive." The present study included the most recently published trials and updates of previous trial reports, thoroughly investigated the efficacy profiles of 21 treatment options, and avoided certain limitations of previous NMAs mentioned above.

According to our results, the combination of daratumumab, lenalidomide, and dexamethasone was most effective in terms of NRR, TTP, and PFS. However, in terms of OS, it was less effective compared with the combination of ixazomib, lenalidomide, and dexamethasone. Ranking by overall efficacy showed that the daratumumab, lenalidomide, and dexamethasone triplet regimen had better performance than other regimens. Interestingly, we noted that the 21 regimens investigated in this NMA can be categorized into three subgroups based on the weighted average of SUCRA scores. The first subgroup includes four regimens (19.0%, weighted average from \~0.8 to \~0.9), which are the most effective ones, with lenalidomide and dexamethasone as the backbone plus one of the four latest agents (daratumumab, ixazomib, carfilzomib, or elotumumab). The second subgroup includes 11 regimens (52.4%, weighted average from \~0.4 to \~0.7), which show moderate efficacy in RRMM patients and are mostly doublet or triplet regimens. The third subgroup includes six regimens (28.6%, weighted average from 0.0 to 0.25), which are mostly singlet or doublet regimens having limited efficacy.

An important advantage of NMA over traditional meta-analysis is the possibility of ranking multiple treatment options. The SUCRA score, derived from the probability that a given treatment has a certain rank and calculated from the posterior distributions of all treatments, is widely used for ranking treatments in Bayesian NMAs. In this study, we applied a weighted averaging strategy to rank the regimens for overall efficacy. We assigned weights to different outcome measures in accordance with their importance. The OS is the "gold standard" outcome measure for the evaluation of long-term anticancer efficacy, the PFS and TTP are widely acknowledged surrogates of OS, and the treatment response associated with early efficacy may differ from long-term outcomes. Therefore, we gave a 20%, 35%, and 45% weight to NRR, PFS/TTP, and OS, respectively. We did not take safety into account, because to date no adequate data were available to include all treatment options in one network for any single adverse event outcome. A systematic review less quantitatively intense may be a good choice for further investigation on safety profiles. We do not recommend any ranking based on a combined quantitative analysis of efficacy and safety, because they are two facets distinct from one another, and it is very difficult to assign a rational and appropriate weight to each outcome.

The present study, similar to its preceding works, also has some limitations. First, although the relative importance of different outcome measures was considered, the appropriateness of the arbitrary assignment of weights needs further verification. Besides, it should acknowledge the limitations of the NMA fully when comparing benefits from the experimental treatments in patient populations that differ in previous treatments, cytogenetic risks, subsequent stem-cell transplantation, maintenance therapy, and so on. Although it could be possible to make adjustment by using approaches such as network meta-regression, the immaturity of methodology, limited number of included trials and frequent missingness in certain study-level variables make it difficult and less reliable.

Conclusion
==========

In conclusion, the combination of daratumumab, lenalido-mide, and dexamethasone may currently be the most effective regimen in the population of RRMM patients. Triplet regimens containing daratumumab, ixazomib, carfilzomib, or elotumumab plus lenalidomide and dexamethasone can be recommended as the first-line therapies for RRMM patients.
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###### 

Basic information of included RCT reports

  Authors                                Year   Trial Identification   Arm 1             Arm 2       N     Outcome
  -------------------------------------- ------ ---------------------- ----------------- ----------- ----- -------------------
  Richardson et al[@b11-cmar-10-2817]    2005   APEX                   BOR               DEX         627   NRR, TTP, OS
  Richardson et al[@b12-cmar-10-2817]    2007   APEX                   BOR               DEX         627   NRR, TTP, OS
  Dimopoulos et al[@b13-cmar-10-2817]    2007   MM-010                 LEN + DEX         DEX         351   NRR, TTP, OS
  Orlowski et al[@b14-cmar-10-2817]      2007   DOXIL-MMY-3001         BOR + plDOX       BOR + DEX   646   NRR, TTP, PFS, OS
  Weber et al[@b15-cmar-10-2817]         2007   MM-009                 LEN + DEX         DEX         353   NRR, TTP, OS
  Chanan-Khan et al[@b16-cmar-10-2817]   2009   GMY302                 OBL + DEX         DEX         224   NRR, TTP
  Dimopoulos et al[@b17-cmar-10-2817]    2009   MM-009 & MM-010        LEN + DEX         DEX         704   PFS, OS
  Garderet et al[@b18-cmar-10-2817]      2012   MMVAR/IFM 2005-04      BOR + THA + DEX   THA + DEX   244   NRR, TTP, PFS, OS
  Hjorth et al[@b19-cmar-10-2817]        2012   NCT00602511            THA + DEX         BOR + DEX   131   NRR, PFS, OS
  Kropff et al[@b20-cmar-10-2817]        2012   OPTIMUM                THA               DEX         499   NRR, TTP, PFS, OS
  Dimopoulos et al[@b21-cmar-10-2817]    2013   VANTAGE 088            VOR + BOR         BOR         635   NRR, TTP, PFS, OS
  San-Miguel et al[@b4-cmar-10-2817]     2013   MM-003                 POM + DEX         DEX         455   NRR, TTP, PFS, OS
  White et al.[@b22-cmar-10-2817]        2013   AMBER                  BEV + BOR         BOR         102   NRR, PFS, OS
  Morgan et al[@b6-cmar-10-2817]         2014   MM-003                 POM + DEX         DEX         455   OS
  Richardson et al[@b5-cmar-10-2817]     2014   MM-002                 POM + DEX         POM         221   NRR, PFS, OS
  San-Miguel et al[@b23-cmar-10-2817]    2014   PANORAMA1              PAN + BOR + DEX   BOR + DEX   768   NRR, TTP, PFS, OS
  Lonial et al[@b24-cmar-10-2817]        2015   ELOQUENT-2             ELO + LEN + DEX   LEN + DEX   646   NRR, PFS
  Orlowski et al[@b25-cmar-10-2817]      2015   NCT00401843            SIL + BOR         BOR         268   NRR, TTP, PFS, OS
  Stewart et al[@b26-cmar-10-2817]       2015   ASPIRE                 CAR + LEN + DEX   LEN + DEX   792   NRR, PFS, OS
  Dimopoulos et al[@b27-cmar-10-2817]    2016   POLLUX                 DAR + LEN + DEX   LEN + DEX   557   NRR, TTP, PFS, OS
  Dimopoulos et al[@b28-cmar-10-2817]    2016   ENDEAVOR               CAR + DEX         BOR + DEX   929   NRR, PFS, OS
  Jakubowiak et al[@b29-cmar-10-2817]    2016   NCT01478048            ELO + BOR + DEX   BOR + DEX   152   NRR, PFS, OS
  Moreau et al[@b30-cmar-10-2817]        2016   TOURMALINE-MM1         IXA + LEN + DEX   LEN + DEX   722   NRR, TTP, PFS
  Orlowski et al[@b31-cmar-10-2817]      2016   DOXIL-MMY-3001         BOR + plDOX       BOR + DEX   646   OS
  Palumbo et al[@b32-cmar-10-2817]       2016   CASTOR                 DAR + BOR + DEX   BOR + DEX   474   NRR, TTP, PFS, OS
  San-Miguel et al[@b7-cmar-10-2817]     2016   PANORAMA 1             PAN + BOR + DEX   BOR + DEX   768   OS
  Dimopoulos et al[@b8-cmar-10-2817]     2017   ELOQUENT-2             ELO + LEN + DEX   LEN + DEX   646   PFS, OS
  Hou et al[@b10-cmar-10-2817]           2017   NCT01564537            IXA + LEN + DEX   LEN + DEX   115   NRR, TTP, PFS, OS
  Hajek et al[@b9-cmar-10-2817]          2017   FOCUS                  CAR               DEX         315   NRR, PFS, OS

**Abbreviations:** BOR, bortezomib; BEV, bevacizumab; CAR, carfilzomib; DAR, daratumumab; DEX, dexamethasone; plDOX, Pegylated liposomal doxorubicin; ELO, elotumumab; IXA, ixazomib; LEN, lenalidomide; OBL, oblimersen; POM, pomalidomide; SIL, siltuximab; THA, thalidomide; NRR, non-response rate; PAN, panobinostat; PFS, progression-free survival; TTP, time to progression; OS, overall survival; N, number of patients; VOR, vorinostat.

###### 

Included regimens, SUCRAs, weighted averages of SUCRAs across NRR, TTP, and OS, and ranks in terms of overall efficacy

  Regimens                                                                  NRR     TTP     PFS     OS      Weighted average   Rank
  ------------------------------------------------------------------------- ------- ------- ------- ------- ------------------ ------
  Daratumumab + lenalidomide + dexamethasone                                0.984   0.988   0.999   0.829   0.920              1
  Ixazomib + lenalidomide + dexamethasone                                   0.828   0.828   0.869   0.972   0.907              2
  Carfilzomib + lenalidomide + dexamethasone                                0.964   NA      0.887   0.697   0.817              3
  Elotuzumab + lenalidomide + dexamethasone                                 0.873   NA      0.855   0.72    0.798              4
  Daratumumab + bortezomib + dexamethasone                                  0.813   0.927   0.812   0.539   0.689              5
  Pomalidomide + dexamethasone                                              0.539   0.393   0.512   0.771   0.634              6
  Carfilzomib + dexamethasone                                               0.683   NA      0.638   0.527   0.597              7
  Lenalidomide + dexamethasone                                              0.66    0.609   0.685   0.447   0.572              8
  Bortezomib + thalidomide + dexamethasone                                  0.202   0.531   0.581   0.689   0.554              9
  Bevacizumab + bortezomib                                                  0.5     NA      0.38    0.656   0.528              10
  Elotuzumab + bortezomib + dexamethasone                                   0.429   NA      0.358   0.564   0.465              11
  Pomalidomide monotherapy                                                  0.252   NA      0.25    0.698   0.452              12
  Vorinostat + bortezomib                                                   0.661   0.446   0.342   0.433   0.447              13
  Panobinostat + bortezomib + dexamethasone                                 0.472   0.678   0.566   0.327   0.43965            14
  Pegylated liposomal doxorubicin + bortezomib                              0.406   0.715   0.55    0.305   0.41095            15
  Thalidomide ± dexamethasone                                               0.083   0.153   0.221   0.325   0.2402             16
  Bortezomib ± dexamethason                                                 0.329   0.263   0.149   0.235   0.2237             17
  Siltuximab + bortezomib                                                   0.511   0.391   0.259   0.048   0.21445            18
  Carfilzomib monotherapy                                                   0.214   NA      0.029   0.132   0.11235            19
  Dexamethasone monotherapy                                                 0.057   0.068   0.059   0.089   0.0721             20
  Oblimersen + dexamethasone[\*](#tfn3-cmar-10-2817){ref-type="table-fn"}   0.041   0.011   NA      NA      0.017              21

**Notes:** A 20%, 35%, and 45% weight was given to the NRR, PFS, and OS, respectively.

Since data on PFS and OS were not available, a 20% and 80% weight was assigned to NRR and TTP, respectively.

**Abbreviations:** NA, not available; NRR, non-response rate; TTP, time-to-progression; PFS, progression-free survival; OS, overall survival.
